CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
MK-0941 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00754130
NCT00754130Phase 1Completed
CompareCT.gov

A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 in Japanese Patients With Type 2 Diabetes

Merck Sharp & Dohme LLC·interventional·Posted Sep 17, 2008·Updated Mar 12, 2015

In Brief

A Phase 1 clinical trial evaluating Placebo and MK-0941 for Diabetes Mellitus, Non-Insulin-Dependent. Completed, enrolled 16 participants.

Detailed Summary

The multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0941 in Japanese patients with Type 2 Diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Non-Insulin-Dependent
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 17, 2008
Enrollment StartSep 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.8 years ago

Interventions

Placebodrug

Placebo tablets before every meal (q.a.c) Treatment period is 5 days.

MK-0941drug

MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.